January 4th, 2009

Patty Duke To Share Story Of Mental Illness In Sarasota
Actress To talk About Bipolar Disorder At Symposium

By Donna Wright - Bradenton Herald
Jan 4, 2009

“A Brilliant Madness” is how actress Patty Duke describes her battle with bipolar disorder and its impact on her highly successful career that includes an Academy Award for a performance as Helen Keller in the “The Miracle Worker.”

“There is something going on inside me, in my eyes, in the cells of my face that is, in a strange way, so alive and yet so mysterious,” Duke writes in her memoir, co-authored by Gloria Hochman. “Is that mystery the gift? Is it the illness? Is it a certain intelligence? Or fear? In my opinion, it has to be a combination of all of those things.”

For Elyn R. Saks, associate dean at the University of Southern California, with triple appointments as a professor of law, psychology and psychiatry, “schizophrenia rolls in like a slow fog, becoming imperceptibly thicker as time goes on . . . After a while the sun is a dim light bulb behind a heavy cloth. The horizon has vanished into a grey mist and you feel a thick dampness in your lungs as you stand, cold and wet, the afternoon of the dark.”

In her highly acclaimed biography, “The Center Cannot Hold” Saks takes the reader along in her descent into madness and her ascent to a normal life through successful treatment.

Duke and Saks will share their struggles and ongoing recovery at the “Journey into Wellness from Mental Illness” a free community education program, 9 a.m. to 12:30 p.m. next Saturday at Van Wezel Performing Arts Hall. Sponsored by Sunshine From Darkness, (formerly NARSAD Florida), the weekend event includes a black tie gala Sunday evening when Duke, along with Lee and Bob Peterson, founders of NARSAD Florida will receive Luminary Awards for their advocacy for the mentally ill.

In exclusive interviews with the Bradenton Herald, Duke and Saks talked about how their lives have changed as the result of successful treatment and going public with their own battles.

For Duke, going public has had positive results.

“Being an advocate strengthens you,” Duke said. “One of the things people with mental illness sense is that we are truly alone in the world, but the more we talk about it the more realize that’s not true.”

Duke has found that sharing her story helps silent sufferers to speak up. “It is always remarkable to me when I stand in front of people and say you can recover. For some it may give that little push to go have it checked out,” she said.

In turn, Duke believes those conversations about mental illness are helping to dispel the public’s fear.

“I don’t know that there is significant change, but I see a forward thrust,” Duke said. “People on TV talk about mental illness openly. You can strike up a conversation on an airplane and find out that if not that person, then someone they know has a problem.”

But even when they open up, some people hold back, says Duke. “They are willing to talk about it, but many are not willing to go for help because of fear of the unknown. That’s why my saying, ‘I am going to show you mine and you can show my yours, if you want,’ helps breaks down barriers. I didn’t think there was any hope for me. Now I know there is hope.”

Still, mental illness carries a stigma that blocks support for more research and treatment options, says Saks.

“One of the reasons more people don’t support mental health programs is they don’t understand what mental illness and they fear people who are mentally ill,” Saks said. “In these economic hard times, treatment and intervention are less available. I count my lucky stars that I have had access to treatment.”

“We are a very judgmental society,” Duke said. “As much as we may be informed, there is still that shadow, that fear. Don’t go near that person, that person is nuts.”

Both Saks and Duke lament the disparity in mental health care.

“What we are trying to do is to connect with the government, so we can get more funding,” Duke said. “We had just a fraction of the money going toward heart disease and cancer research it would benefit thousands of people.”

“The loss is measured in lost lives and contributions to society,” says Saks. “It’s a tragedy that most people don’t get the help they need. If they got help, they would be much happier and higher-functioning.”

She fervently believes that people with mental disorders should be allowed to pursue their dreams.

“People think they are doing the right thing when they tell someone who has been diagnosed to lower expectations,” Saks said. “I say shoot for the stars to do the things you have always dreamed of doing before you got sick. To tell people to lower their expectations is to do them a great disservice.”

Saks is currently conducting a research study of schizophrenics who, like herself, have become very successful in the careers through treatment of their mental illnesses. Her goal is try to determine what common denominators might exist among the study group that may be the basis for treatment options for others with the same diagnosis.

I do believe that most psychiatric illnesses are biochemical,” Saks said. “Stress exacerbates illness. If you keep someone stress-free, they will do better.”

Learning how to recognize the onset of her psychotic episodes helped Saks develop ways to handle them, especially by avoiding overstimulation.

“Stressful situations can cause me to have a break,” said Saks. “My husband likes to say that psychosis is not an off/on switch but dimmer switch. At the one end I could be confused. At the far end at I could be cowering in the corner.”

Psychoanalysis, Saks says, helped her learn how to identify her delusions, allowing her to understand their relationship to reality. To date, Saks has not had a major psychotic episode since 2001.

Treatment, Duke says, helped her become more creative. By leveling out her highs and lows of her mood cycles, she was able to focus on her acting. Ironically that focus, Duke says, was heightened by her fear of death, which she admits is her greatest fear.”

Popularity: 36% [?]

Share This Post

Show Love (No Ratings Yet)
Loading ... Loading ...
November 15th, 2008

Wall Street Journal - Market Watch
New Data, New Directions in the Management of Mood and Anxiety Disorders

VIENNA, Austria, November 14, 2008 /PRNewswire via COMTEX/ — - 8th International Forum for Mood and Anxiety Disorders Congress Roundup
Clinicians and researchers from around the world attended this week’s 8th International Forum on Mood and Anxiety disorders in Vienna, Austria to discuss the latest advances in the treatment of mood disorders.
A wide range of topics were included in this year’s programme, highlighting the position of IFMAD in the congress calendar as a forum for breaking news, original thinking and debate.
Highlights from the meeting included the latest new treatments for depression and anxiety disorders. There was the first comprehensive presentation of data demonstrating that quetiapine has clear cut efficacy in major depressive disorder (MDD), including a study in the elderly, a difficult to treat and under-researched patient population. It is also the first time that an antidepressant has shown consistent early efficacy at one week in both MDD and bipolar depression. Delegates were excited at the announcement at IFMAD of the first EU licence within the EU for a treatment for bipolar depression.
This year’s IFMAD reflected the rapid pace in which new discoveries are being made to improve our understanding of the mechanisms of mood disorders, the underlying neurobiology and the role of antidepressant treatment. Data evaluating a wide range of potential treatment directions were presented, including studies on the antidepressant agomelatine which targets melatonin and serotonin receptors in the brain. Other new data were presented showing that as much as 30 percent of unipolar depression has genetic or symptomatic predictors for the development of bipolar disorder and the delegates agreed that this was an important area for further research and the targeting of new treatments.
“We are living in exciting times for the treatment of mood disorders with new approaches and new targets being discovered and explored all of the time,” said Professor Siegfried Kasper, IFMAD Chairman and Professor of Psychiatry, Head of the Department of Psychiatry and Psychotherapy at the Medical University of Vienna, Austria. “The breadth of data presented at this year’s IFMAD has really demonstrated this, providing delegates with a comprehensive update of cutting edge advances in the field.”
Other elements of the meeting included an important debate on the relationships between pain, anxiety and depression and the continuing problem of under-diagnosis of GAD despite its prevalence and significant burden to society. The vital need to ensure patient concordance in the treatment of depression and anxiety was discussed, including the roles of patient education, monitoring and the selection of treatments with minimal side effects.
“The format of IFMAD allows informal debate and brings together leaders in the field of mood and anxiety disorders to discuss the most pressing topics and issues of the moment,” said Professor Stuart Montgomery, IFMAD Co-Chairman and Emeritus Professor of Psychiatry, Imperial College of Medicine, University of London, UK. “What sets IFMAD apart is that the meeting is friendly and small enough to allow that informal exchange of new and emerging data from around the world.”
This year’s meeting also marked the launch of the new IFMAD website, providing an online forum to ensure that clinicians and researchers can access the latest developments in mood disorders throughout the year. A full roundup of the 8th IFMAD meeting, including the final abstract book, will be available shortly on the new website, http://www.ifmad.org.
Notes to Editors
About IFMAD
IFMAD is a professional organisation dedicated to raising awareness of the latest international thinking and innovations in mood and anxiety disorders and promoting the exchange of ideas across the global psychiatric community.
IFMAD was founded in 2001 by Professor Siegfried Kasper and Professor Stuart Montgomery, supported by a scientific committee consisting of leading figures in mood and anxiety disorders from around the world.
IFMAD organises a yearly congress to promote debate and highlight the latest research in mood and anxiety disorders. Now in its ninth year, the annual event has become an important forum for the exchange of ideas and a key part of the congress calendar.
Sponsors of this year’s IFMAD meeting included H.Lundbeck A/S, who also supported the development of the new IFMAD website through an unrestricted educational grant, Astra Zeneca, Pierre Fabre Medicament, Servier and Wisepress Ltd.
SOURCE IFMAD ”

Popularity: 46% [?]

Share This Post

Show Love (No Ratings Yet)
Loading ... Loading ...